"

亚游会游戏平台_亚游会游戏平台官方拥有全球最顶尖的原生APP,每天为您提供千场精彩体育赛事,亚游会游戏平台_亚游会游戏平台官方更有真人、彩票、电子老虎机、真人电子竞技游戏等多种娱乐方式选择,亚游会游戏平台_亚游会游戏平台官方让您尽享娱乐、赛事投注等,且无后顾之忧!

                      "

                      专家论坛

                      Expert forum

                      首页 专家论坛 标本专家Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells.
                      注册

                      Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells.

                      2017-12-08 08:13来源:原版作者:Stovold R

                      Small cell lung cancer (SCLC) is characterised by an aggressive clinical course with invariable resistance to chemotherapy despite initially high response rates. There has been little improvement in outcome over the past few decades, with no breakthrough yet in targeted therapies. Recent preclinical data and studies of circulating tumour cells (CTCs) highlight distinct cellular heterogeneity within SCLC. Better understanding of how these phenotypes contribute to metastasis and tumour progression might pave the way for development of more successful targeted therapies. Here we review these studies, their implications for future research and for the incorporation of biomarkers reflecting neuroendocrine, epithelial and mesenchymal phenotypes in clinical studies.

                      (Lung Cancer. 2012 Jun;76(3):263-8. )

                      版权声明:

                      本网站所有注明“来源:“阳普医疗”的文字、图片和音视频资料,版权均属于阳普医疗所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明

                      “来源:阳普医疗”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

                      网友评论:

                      亚游会游戏平台_亚游会游戏平台官方